Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$11.2 million.

  • Spyre Therapeutics' Consolidated Net Income rose 8379.93% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 3068.05%. This contributed to the annual value of -$208.0 million for FY2024, which is 3859.97% up from last year.
  • Per Spyre Therapeutics' latest filing, its Consolidated Net Income stood at -$11.2 million for Q3 2025, which was up 8379.93% from -$36.7 million recorded in Q2 2025.
  • Spyre Therapeutics' Consolidated Net Income's 5-year high stood at -$6.8 million during Q2 2021, with a 5-year trough of -$217.1 million in Q2 2023.
  • For the 5-year period, Spyre Therapeutics' Consolidated Net Income averaged around -$41.5 million, with its median value being -$24.4 million (2022).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first tumbled by 87245.44% in 2023, then surged by 8379.93% in 2025.
  • Over the past 5 years, Spyre Therapeutics' Consolidated Net Income (Quarter) stood at -$20.4 million in 2021, then grew by 7.94% to -$18.8 million in 2022, then tumbled by 235.67% to -$63.2 million in 2023, then increased by 10.9% to -$56.3 million in 2024, then soared by 80.14% to -$11.2 million in 2025.
  • Its Consolidated Net Income was -$11.2 million in Q3 2025, compared to -$36.7 million in Q2 2025 and -$44.8 million in Q1 2025.